Inclusion Criteria:

          -  Histologically confirmed invasive cancer of the breast

          -  Clinically or radiologically measureable disease in the breast after diagnostic
             biopsy, defined as longest diameter greater than or equal to 25 mm (2.5cm)

          -  No prior cytotoxic regimens are allowed for this malignancy. Patients may not have had
             prior chemotherapy or prior radiation therapy to the ipsilateral breast for this
             malignancy. Prior bis-phosphonate therapy is allowed

          -  Age ≥18 years

          -  ECOG performance status 0-1

          -  Willing to undergo core biopsy of the primary breast lesion to assess baseline
             biomarkers

          -  Non-pregnant and non-lactating

          -  No ferromagnetic prostheses. Patients who have metallic surgical implants that are not
             compatible with an MRI machine are not eligible.

          -  Ability to understand and willingness to sign a written informed consent (I-SPY TRIAL
             Screening Consent)

          -  Eligible tumors must meet one of the following criteria: Stage II or III, or T4, any
             N, M0, including clinical or pathologic inflammatory cancer or Regional Stage IV,
             where supraclavicular lymph nodes are the only sites metastasis

          -  Any tumor ER/PgR status, any HER-2/neu status as measured by local hospital pathology
             laboratory and meets any tumor assay profile described in protocol section 4.1.2F

          -  Normal organ and marrow function: Leukocytes ≥ 3000/μL, Absolute neutrophil count ≥
             1500/μL, Platelets ≥ 100,000/μL, Total bilirubin within normal institutional limits,
             unless patient has Gilbert's disease, for which bilirubin must be ≤ 2.0 x ULN,
             AST(SGOT)/ALT (SGPT) ≤ 1.5 x institutional ULN, creatinine < 1.5 x institutional ULN

          -  No uncontrolled or severe cardiac disease. Baseline ejection fraction (by nuclear
             imaging or echocardiography) must by ≥ 50%

          -  No clinical or imaging evidence of distant metastases by PA and Lateral CXR,
             Radionuclide Bone scan, and LFTs including total bilirubin, ALT, AST, and alkaline
             phosphatase

          -  Tumor assay profile must include on of the following: MammaPrint High, any ER status,
             any HER2 status, or MammaPrint Low, ER negative (<5%), any HER2 status, or MammaPrint
             Low, ER positive, HER2/neu positive by any one of the three methods used (IHC, FISH,
             TargetPrint™)

          -  Ability to understand and willingness to sign a written informed consent document
             (I-SPY 2 TRIAL Consent #2)

        Exclusion Criteria:

          -  Use of any other investigational agents within 30 days of starting study treatment

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to the study agent or accompanying supportive medications.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements